Bone metastases: Are we failing our patients?
作者信息
Tombal B, Diel I, Drudge-Coates L, Haynes I, Brodowicz T
机构信息
Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, B-1200 Brussels, Belgium.
CGG-Klinik Mannheim, Gynäkologischer Onkologe, Quadrat P7, 16-18, 68161 Mannheim, Germany.
出版信息
J Bone Oncol. 2014 Mar 26;3(2):37-9. doi: 10.1016/j.jbo.2014.03.001. eCollection 2014 May.
Abstract
摘要
相似文献
1
Bone metastases: Are we failing our patients?骨转移：我们是否辜负了患者？
J Bone Oncol. 2014 Mar 26;3(2):37-9. doi: 10.1016/j.jbo.2014.03.001. eCollection 2014 May.
2
Bisphosphonates and other bone agents for breast cancer.用于乳腺癌的双膦酸盐及其他骨药物。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD003474. doi: 10.1002/14651858.CD003474.pub3.
3
Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review.双膦酸盐、地舒单抗和放射性核素对非小细胞肺癌伴骨转移患者骨痛和生活质量的影响：系统评价。
J Thorac Oncol. 2016 Feb;11(2):155-73. doi: 10.1016/j.jtho.2015.10.001. Epub 2015 Dec 22.
4
Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.检查初治地舒单抗和静脉用双膦酸盐治疗实体瘤骨转移患者的骨骼相关事件负担。
Curr Med Res Opin. 2019 Mar;35(3):513-523. doi: 10.1080/03007995.2018.1532884. Epub 2018 Nov 20.
5
Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.地舒单抗与双膦酸盐治疗实体瘤骨转移：系统评价。
Eur J Health Econ. 2019 Jun;20(4):487-499. doi: 10.1007/s10198-018-1011-1. Epub 2018 Oct 31.
6
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
7
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.在美国，地舒单抗与唑来膦酸预防实体瘤伴骨转移患者骨骼相关事件的成本效果比较。
J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.
8
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2002(1):CD003474. doi: 10.1002/14651858.CD003474.
9
Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.地舒单抗与双膦酸盐类药物在晚期癌症骨转移患者中的疗效比较：随机对照试验的系统评价和荟萃分析。
Support Care Cancer. 2018 Apr;26(4):1029-1038. doi: 10.1007/s00520-018-4060-1. Epub 2018 Feb 1.
10
Rethinking end-points for bone-targeted therapy in advanced cancer.重新思考晚期癌症骨靶向治疗的终点。
Eur J Cancer. 2016 Aug;63:105-9. doi: 10.1016/j.ejca.2016.05.014. Epub 2016 Jun 11.
本文引用的文献
1
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer.静脉用双膦酸盐在乳腺癌、肺癌或前列腺癌骨转移患者中的应用。
Support Care Cancer. 2014 Jan;22(1):103-13. doi: 10.1007/s00520-013-1951-z. Epub 2013 Sep 3.
2
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.地舒单抗优于唑来膦酸预防骨骼相关事件：3 项关键性、随机、3 期临床试验的联合分析。
Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.
3
Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.口腔护理对预防双膦酸盐相关性颌骨骨坏死的影响：单中心临床经验。
Ann Oncol. 2012 Jan;23(1):193-200. doi: 10.1093/annonc/mdr039. Epub 2011 Mar 22.
4
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.在接受唑来膦酸治疗的多发性骨髓瘤患者中实施预防措施后，颌骨骨坏死（ONJ）的发生率降低。
Ann Oncol. 2009 Jan;20(1):117-20. doi: 10.1093/annonc/mdn554. Epub 2008 Aug 9.
5
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.在接受双膦酸盐治疗的实体瘤骨转移患者中实施牙科预防措施后，颌骨骨坏死发生率降低。米兰国家癌症研究所的经验。
Ann Oncol. 2009 Jan;20(1):137-45. doi: 10.1093/annonc/mdn526. Epub 2008 Jul 22.
6
Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.唑来膦酸在预防骨转移患者骨骼并发症方面的持续益处。
Clin Genitourin Cancer. 2007 Sep;5(6):390-6. doi: 10.3816/CGC.2007.n.022.
7
Clinical features of metastatic bone disease and risk of skeletal morbidity.转移性骨病的临床特征与骨骼并发症风险
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s. doi: 10.1158/1078-0432.CCR-06-0931.
8
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.肺癌骨转移患者骨相关事件的治疗费用。
Oncology. 2004;67(5-6):390-6. doi: 10.1159/000082923.
9
Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.骨转移的病理生理学：这些知识如何导向治疗干预。
J Support Oncol. 2004 May-Jun;2(3):205-13; discussion 213-4, 216-7, 219-20.
10
Mechanisms of bone metastasis.骨转移的机制。
N Engl J Med. 2004 Apr 15;350(16):1655-64. doi: 10.1056/NEJMra030831.
Zotero 插件